Stock Price Target

Recent Price Targets: [Sign In or Register (FREE) to view]
Last Price Avg Target Price   Upside/Downside Price Call
1.20 1.57     +0.37 (30.83%)
* Average Target Price, Price Call and Upside/Downside are derived from Price Targets in the past 6 months.
** Price Targets are adjusted for Bonus Issue, Shares Split & Shares Consolidation (where applicable).
Date Open Price Target Price Upside/Downside Price Call Source News
22/03/2019 1.20 1.61 +0.41 (34.17%) BUY TA Price Target News
08/03/2019 1.14 1.52 +0.38 (33.33%) BUY TA Price Target News
19/02/2019 1.08 1.52 +0.44 (40.74%) BUY TA Price Target News
29/11/2018 1.08 1.52 +0.44 (40.74%) BUY TA Price Target News

Price Target Research Article/News (past 6 months)
22/03/2019  TA Duopharma Biotech Berhad - Expecting FY19 to be a Stronger Year
08/03/2019  TA Duopharma Biotech Berhad - EPO and Oncology the Growth Engines
19/02/2019  TA CCM Duopharma Biotech Bhd - Improved Profitability in 4Q18
29/11/2018  TA CCM Duopharma Biotech Bhd - Outlook Remains Stable

  4 people like this.
chandra54 yeah romyzam, will go hopless yet again. forget to smell 1.27. this prise is history
18/09/2018 1:03 PM
chandra54 Post removed. Why?
18/09/2018 1:04 PM
Jordan Khoo Good show ! Very strong... will move tomorrow and profit incoming
18/09/2018 3:26 PM
Gavin Chua may i know CCMBIO's competitors ?
18/09/2018 10:57 PM
jibbie pharmaniaga, yspsah, hovid
19/09/2018 4:38 PM
Romyzam Nice recovery today. More to come tomorrow. Really hope back to 1.27 and above...
19/09/2018 6:28 PM
chandra54 Post removed. Why?
25/09/2018 10:15 AM
Romyzam Cool Chandra. Now accumulation time. I bought total 100k shares from 1.15 to 1.19. If break 1.14 again then cut lo
25/09/2018 11:58 AM
Romyzam Nicely back to 1.26 today.
26/09/2018 1:16 PM
Romyzam Sold back all 1.23 to 1.26. Good luck those still holding. Good counter but too slow. Thanks ccmdbio for the quick bucks.
02/10/2018 7:14 PM
Investeye Take opportunity to accumulate more based on EPF kept accumulating recently. In fact after holding some lots for 1.5 yrs, it is still gaining at this price ( due to bonus 4:3 issuing 15 maths ago)
03/10/2018 8:24 PM
04TSH Interesting feedbacks and advices guys
04/10/2018 4:09 PM
Romyzam Buy back 1.12. Cheap sale.
11/10/2018 12:05 PM
Stephenloo Declared 1.5 cent dividen
22/10/2018 7:29 PM
YKLIEW Bought 1-28 down 20 sen but get 1.5 sen dividend. Terrible investment yo
02/11/2018 9:45 PM
moneytrail Collect for long term, consistent profit this 2 years. Factory expansion to bear fruit 2020. Niche product and stem cells product, hope to give higher margin to offset margin erosion from competitive generic drugs.
03/11/2018 3:46 PM
jinghee Will the government budget benefit this company?
08/11/2018 8:55 PM
Hafid people are selling
15/11/2018 4:16 PM
kmwong8711 Today quarter results out??
16/11/2018 10:55 AM
necro I must said recent acquisition & ventures were uninteresting to investor, too many drug & substances in pipeline. Investor dont understand of what is the drug is going to do with Malaysia market.

Asean is not like Singapore, Japan or Korea where the country spend 7% of GDP for healthcare budget, Malaysia for example is only use of 3% GDP for healthcare budget.

Malaysia healthcare priority budgeting only for "3 serangkai" diseases which diabetes, high blood pressure & heart diseases. Disease like autoimmune, chronic kidney disease(ckd), obstetric &, gynaecology using advance medication were too expensive for government to used.

Hopefully CEO does not to eager to pursuing pipeline quantity but focus more on quality, he must realise that that CCMDBIO is conglomerates not science lab where he can test new drug or substances onto Malaysian people.
22/11/2018 9:55 AM
moneytrail Good resukts
28/11/2018 10:56 PM
Tete7893 Luckily run early.
26/12/2018 5:45 PM
Yi Heng 0.94 all in
22/01/2019 7:22 PM
Nicholasming91 Can buy wow
18/02/2019 7:01 PM
Yi Heng yes, dividend 4 sen if approved
18/02/2019 7:23 PM
Investeye CCM Duopharma Biotech Bhd’s fourth quarter net profit rose 18.45% to RM14.37 million from RM12.13 million a year ago, due to higher revenue and changes in accounting policies arising from adoption of the Malaysian Financial Reporting Standards 9 (MFRS 9).
Earnings per share for the quarter ended Dec 31, 2018 rose to 2.17 sen from 1.86 sen.
Quarterly revenue was up 3.01% to RM115.63 million, from RM112.25 million previously, the group said in a filing with Bursa Malaysia.
CCM Duopharma has declared a final dividend of four sen, bringing total payout for FY18 to 5.5 sen, as against 3.64 sen in FY17.
The group has also proposed that the dividend reinvestment plan would apply to the final dividend.
For FY18 as a whole, CCM Duopharma’s net profit increased 12.19% to RM47.64 million or 7.26 sen per share from RM42.46 million or 6.52 sen per share last year, while revenue grew 6.57% to RM498.72 million from RM467.99 million.
On prospects, the group said it sees opportunities from the increase in allocation for health services to RM29 billion in Budget 2019 including RM10.8 billion to restore clinics and hospitals as well to buy medicine and medical equipment.
“The group will also continue its foray into the specialty products as one of its strategies moving forward to create a pool of niche products,” said CCM Duopharma, adding that it has recently received registration approval for Erysaa, an erythropoeitin product.
Barring any unforeseen circumstances, the group expects to achieve satisfactory results in FY19.
18/02/2019 10:08 PM
shpg22 Liquidity has deteriorated quite rapidly, still able to give 4cents dividend. Good management
18/02/2019 10:49 PM
chshzhd good dividend
19/02/2019 10:41 AM
chshzhd but profit improved is due to adoption of MFRS.
19/02/2019 10:45 AM
Yi Heng wait it correction and buy again :)
19/02/2019 12:30 PM
tac2255 finally it gap up
19/02/2019 4:14 PM
LOLANTO what correction.... it's just the very beginning of the rally. buy before it is too late!
19/02/2019 8:20 PM
James Ng https://klse.i3investor.com/blogs/general/194224.jsp
[转贴] [CCM DUOPHARMA BIOTECH BHD:进军特种产品,作为其创建一系列利基产品的战略之一,它最近获得了红细胞生成素产品Erysaa的注册批准] - James的股票投资James Share Investing
20/02/2019 11:52 AM
Investeye SHAH ALAM (Feb 20): CCM Duopharma Biotech Bhd (CCMD) is hopeful of getting its RM10 million goods and services tax (GST) refund from the government within this year.

"We are in the process [of getting the refund]. There are still questions that need to be addressed with the Ministry of Finance (MoF), but we are quite happy with the announcement about the refund. Hopefully, it will be refunded within this financial year," CCMD group managing director Leonard Ariff Abdul Shatar told the press at its extraordinary general meeting (EGM) here.

Last August, Leonard Ariff told The Edge Financial Daily that the government still owed CCMD about RM10 million in GST refunds.
20/02/2019 5:07 PM
factorrumour "A final dividend of 4.0sen/share was proposed (FY18: 5.5sen/share vs. FY17: 3.6sen/share). This translates to a dividend payout ratio of 68%, which is much higher than FY17 payout ratio of 55%."

how did this guy get FY17: 3.6sen/share?
22/02/2019 10:38 PM
factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!
25/02/2019 10:51 PM
cmshyong when is the ex date for 4 sen dividen?
26/02/2019 7:35 PM
catchcon factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!

It's good brother, better things to come.
11/03/2019 5:13 AM
chshzhd @factorrumour div for fy17 was 3.6sen bcos the adjustment of bonus issue at june last year
12/03/2019 11:43 AM
chshzhd ..so div 5.5sen for fy18 actually is an improvement of 55% !
12/03/2019 11:45 AM
chshzhd @cmshyong the ex date for 4 sen will be around june this year.
12/03/2019 11:46 AM
Chengkai Kok 目标价:1.52令吉









12/03/2019 1:26 PM
keyin Why no movement,boring
16/03/2019 12:16 PM
Manekineko Hahaha, healthcare counter is like that la... Slow but steady...
18/03/2019 12:32 PM
Dakewlest Moving up. Any TP, anyone?
21/03/2019 6:49 PM
keyin Tp3
21/03/2019 7:15 PM
kmwong8711 For me above 1.30 is good
21/03/2019 7:59 PM
k3nthiew go! go! go!
22/03/2019 9:05 AM
k3nthiew Getting contract soon?
22/03/2019 9:05 AM
Investeye TA Research - 22 Mar 2019 Valuation & Recommendation :
We maintain Buy on Duopharma with a higher TP of RM1.61/share (previously RM1.52/share) based on unchanged 20.0x CY19 PER. We continue to like Duopharma for its: i) strong market share in Malaysia, and ii) move into niche pharmaceuticals products.
22/03/2019 9:41 AM

353  351  537  671 

Top 10 Active Counters
 BJCORP 0.2650.00 
 HIBISCS 1.10+0.04 
 MYEG 1.39+0.09 
 SAPNRG-WA 0.1450.00 
 DYNACIA 0.095-0.005 
 ORION 0.215+0.015 
 DAYANG 1.33-0.06 
 HSI-C5D 0.34-0.015 
 SAPNRG 0.345-0.005 
 HSI-C3V 0.05-0.015 
Partners & Brokers